Ares Trading S.a.

Applied Research Systems Ars Holding N.v.

Merck Serono S. A.

Fabrizio Samaritani

Alessandra Del Rio

Patrizia Natale

Rita Agostinetto

Piergiorgio Donati

Joel Richard

Filippo Rendina

The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Liquid formulations of tumor necrosis factor-binding proteins

The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.

LH liquid formulations

Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose.

GRF-containing lyophilized pharmaceutical compositions

A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, a surfactant, an isotonicity agent and an antioxidant. Preferably the interferon is human recombinant IFN-beta.

Human serum albumin-free stabilized interferon liquid formulations

A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON (polytetrafluoruethylene (PTFE)) and contains a HSA-free Interferon-&#x3b2; formulation having the following composition: 30 to 100 &#x3bc;g/ml of interferon-&#x3b2;, an isotonicity agent, 0.1 to 2 mg/ml of Poloxamer 188, at least 0.12 mg/ml of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.

Stabilized liquid protein formulations in pharmaceutical containers

The invention relates to the field of pharmaceutical formulations of a mixture of follicle stimulating hormone (FSH) and luteinising hormone (LH), and to methods of producing such formulations.

Freeze-dried FSH/LH formulations

The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic&#xae; F77, Pluronic F87, Pluronic F88 and Pluronic F68.

Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant

A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, an amino acid and an antioxidant. Preferably, the interferon is human recombinant IFN-beta.

Stabilized interferon liquid formulations

Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-beta is preferably recombinant.

IFN-&#x3b2; liquid formulations

Interferon-&#x3b2; liquid formulations stabilized with a polyol, a non-reducing sugar or an amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-&#x3b2; is preferably recombinant.

Growing community of inventors

Rome, Italy

Fabrizio Samaritani